Surveillance for resistance to antiviral medications used for influenza treatment is important in determining how the drugs can be used for disease control. The development of neuraminidase inhibitors (NAIs) and the emergence of avian A(H5N1) influenza as a pandemic threat underscored the need for better knowledge about resistance patterns. Resistance of influenza A viruses to the adamantanes increased globally in 2003 [1] and has since become universal for circulating influenza A(H1N1) and A(H3N2) subtypes. Influenza therapy therefore consists primarily of the NAIs oseltamivir and zanamivir, which are widely licensed internationally.
Naturally occurring resistance to NAIs (ie, occurring without treatment pressure) was rare in influenza viruses (0.33%) in 2002 [2] , although reports of NAIassociated resistance appeared subsequently [3] [4] [5] .
However, in the 2007-2008 influenza season, naturally occurring oseltamivir resistance associated with the H275Y mutation in neuraminidase (NA) emerged among seasonal influenza A (H1N1) viruses (Brisbane-like strain) [6] . By 2008 , most isolates of this subtype had reduced susceptibility to oseltamivir, at levels likely to affect drug efficacy [7, 8] . That strain was replaced during the 2009-2010 pandemic by a swine-derived variant (A/California/7/2009 [H1N1] and its subsequent lineage, H1N1pdm2009), which was typically oseltamivirsensitive [9] .
Most systematic surveillance now performed aims to identify resistance in circulating strains, collected with imperfect knowledge of antiviral treatment history. In contrast, the Influenza Resistance Information Study (IRIS) is based on data from clinical practice. It is one of the largest surveys to specifically examine the prevalence and development of influenza antiviral resistance during the course of disease and its clinical correlates. This 5-year global study was designed to detect and monitor the frequency of viral resistance to NAIs, and describe characteristics and clinical outcomes of patients according to viral subtype and susceptibility. The current article reports the major findings from the first 3 years of IRIS.
METHODS

Study Conduct
IRIS (NCT00884117) is a 5-year prospective, multicenter, observational study. This report summarizes results from 79 centers (64 primary care centers and 15 hospitals) in the United States, China, France, Germany, Poland, Norway, and Australia from December 2008 to March 2011, comprising 3 Northern and 2 Southern Hemisphere seasons and including the 2009-2010 pandemic. The study was performed in compliance with the principles of the Declaration of Helsinki and its amendments, and in accordance with Good Clinical Practice. The study protocol and amendments were approved by independent ethics committees and institutional review boards at each center.
Patient Selection and Treatment
Adults and children aged ≥1 year were included in the study if they were influenza-positive by rapid test (QuickVue Influenza A + B Test; Quidel Corp) at presentation and/or had predefined clinical signs and symptoms of influenza that had lasted ≤48 hours (≤96 hours for hospitalized adults; no time limit for hospitalized children). All patients or legal guardians provided written informed consent at the time of enrollment. Clinical management, including antiviral treatment, was at the discretion of the attending physician (local site investigator). Centers were selected to achieve the widest geographic coverage possible within each country.
Assessments
Patients were evaluated on day 1 (enrollment), day 6, and day 10. The day 10 visit was added by a protocol amendment in year 2 (16 July 2009); thus, the final study visit for some patients (including all those with seasonal H1 influenza) was day 6. Scores for 7 influenza symptoms (fever, sore throat, nasal congestion, cough, myalgia, fatigue, and headache) were recorded daily by patients on diary cards from day 1 through day 12, each scored on a 4-point scale: 0 (absent), 1 (mild), 2 (moderate), or 3 (severe). These were summed to produce a total symptom score (possible range, 0-21). Symptoms were also assessed by the investigator at each visit, using the same scale. Temperature (oral or tympanic) and adverse events were recorded daily on the diary card. Physicians recorded all patient information on an electronic case record form via a secure data capture system.
Laboratory Evaluations
Throat and posterior nasal swab specimens were obtained on days 1, 3 (self-swab), 6, and 10 and viral load determined using semiquantitative real-time reverse transcription polymerase chain reaction (RT-qPCR) for the matrix genes of influenza A and B viruses (Supplementary Data). Qualitative real-time RT-PCR was used to identify influenza type and subtype.
Resistance testing was performed by phenotyping and sequencing of cultured samples (all viruses) and by mutationspecific RT-PCR on original specimens (influenza A viruses only; no equivalent assay available for influenza B viruses) [10] . Mutation-specific real-time RT-PCR for the NA gene of seasonal H1N1, H3N2, and H1N1pdm2009 viruses was used to detect H275Y, R292K, and E119V mutations.
All day 1, 6, and 10 samples with cycle threshold values of <32 were cultured on Madin-Darby canine kidney cells, then tested for phenotypic NAI susceptibility using a chemiluminescence assay (NA-Star, Applied Biosystems, Foster City, California). The mean IC 50 (concentration of NAI resulting in 50% inhibition of viral NA) was calculated for all samples tested. Extreme outliers (IC 50 values >10-fold or <0.1-fold the day 1 mean) were excluded from this dataset and the mean IC 50 was then recalculated. Outliers were defined as samples with IC 50 values >3 interquartile ranges over the day 1 third quartile IC 50 . Full-gene Sanger sequencing for NA, hemagglutinin, and matrix protein 2 (influenza A only) was also performed on viruses obtained from cultured samples. Sequences were compared with those from reference viruses and analyzed for known resistance mutations for oseltamivir, zanamivir, and the adamantanes, and for nonpolymorphic changes that might potentially affect NAI susceptibility (Supplementary Data).
Biostatistical Evaluations
Kaplan-Meier plots were generated for time to viral RNA clearance (ie, no viral RNA detected by RT-qPCR), and time to resolution of all diary card symptoms. Wilcoxon tests were used to compare outcomes between treated (oseltamivir monotherapy started within 2 days of symptom onset) and untreated patients. Multivariable logistic regression analyses were performed to explore associations between baseline patient characteristics and postbaseline genotypic resistance (determined by mutation-specific RT-PCR). The effect of genotype on viral clearance and symptoms in H1N1pdm2009 patients was analyzed using 2 × 2 contingency tables with statistical significance assessed by Fisher exact test (2-tailed).
RESULTS
Demographic and Clinical Characteristics
A total of 2488 patients were enrolled over a period of 3 years. Following investigation of administrative irregularities at one center, all 59 patients from this center were excluded, giving a total analysis population of 2429. At baseline (day 1), 1799 patients (74.1%) had influenza infections of one strain as confirmed and subtyped by RT-qPCR, of whom 1281 were infected with type A viruses and 518 with type B; 1681 influenza-positive patients (93%) completed the study. Influenza-negative patients were excluded from the analysis, as were those with influenza infections that were not subtyped and those with mixed influenza infections (Supplementary Data).
Baseline characteristics of patients with RT-qPCRconfirmed influenza are shown in Table 1 . The numbers of adults and children ( patients aged <13 years) were very similar, as were numbers of male and female patients. Most patients were enrolled at primary care centers and were unvaccinated; comorbidities were rare (Supplementary Data).
A total of 1041 laboratory-confirmed influenza patients (58%) received influenza antiviral therapy: 1027 received monotherapy (oseltamivir, 997; zanamivir, 23; rimantadine, 4; amantadine, 3) and 12 received oseltamivir combinations (with amantadine [7] , rimantadine [4] , and zanamivir [1] ). Of those receiving oseltamivir alone, 922 (92%) patients were treated within 2 days of symptom onset. Antiviral therapy is summarized by year and viral subtype in Table 2 .
Virologic and Clinical Course
The range of mean viral loads for the viral subtypes on day 1 in adults (log 10 viral particles/mL; determined by RT-qPCR) was 5.58-6.02, decreasing to 3.34-4.00 by day 6 and 2.95-3.59 by day 10 (no day 10 data for seasonal H1N1); viral loads were slightly higher in children, but followed the same pattern over time (Figure 1 ). Analysis of median time to viral clearance is shown in Figure 2 , grouped by infecting viral subtype and antiviral treatment. In most cases, the median time to viral clearance was 7 days, except for treated H1N1pdm2009 patients (6 days). Mean total symptom scores fell markedly after day 1 for all viral subtypes, as shown in Figure 3 . The median time to symptom resolution (no single symptom score >1) was significantly shorter in treated than in untreated patients ( Figure 4 ).
Resistance at Enrollment
The H275Y mutation was detected by mutation-specific RT-PCR in the day 1 samples of all seasonal H1N1 influenza patients who had detectable viral RNA (44/47; recruited from January 2009 to September 2009). The mutation persisted in later samples. Neither H275Y nor other known resistance mutations were detected in day 1 samples from patients with single infections of H1N1pdm2009, H3N2, or type B influenza viruses.
Phenotypic results (IC 50 data) for day 1 samples were obtained from 1683 patients with RT-qPCR-confirmed influenza; these are grouped by viral subtype in Table 3 . All seasonal H1N1 virus samples tested had reduced susceptibility to oseltamivir (mean IC 50 , 150 nM) but not to zanamivir; for other subtypes, the majority of samples tested were sensitive to both NAIs (99%, H1N1pdm2009; 97%, H3N2; 99%, influenza B). A day 1 sample from 1 adult H1N1pdm2009 patient was an extreme outlier to oseltamivir (IC 50 = 7.2 nM); no known NAI resistance mutation was found in this sample by mutationspecific RT-PCR or sequencing. A nonpolymorphic change (D199N in NA) was found by sequencing of the virus cultured Seasonal H1N1  40  7  0  47  22  4  0  26  18  3  0  21   H1N1pdm2009  0  491  408  899  0  264  250  514  0  227  158  385  H3N2  26  40  269  335  6  31  208  245  20  9  61  90   B  26  34  458  518  7  15  234  256  19  19  224 from this sample; D199N was also found by sequencing in H1N1pdm2009 viruses from 2 other samples that were not extreme outliers to oseltamivir (1 outlier; 1 nonoutlier). Day 1 phenotypic outlier samples and hypersusceptible samples are quantified in Table 3 ; except for 1 seasonal H1N1 sample with H275Y, no phenotypic outliers were associated with known resistance mutations (Supplementary Data).
Resistance Emergence After Day 1
H1N1pdm2009 Infections
In 17 patients infected with H1N1pdm2009 viruses (all oseltamivir-treated outpatients), the H275Y resistance mutation was detected by mutation-specific RT-PCR in uncultured swab samples collected after day 1 (Supplementary Table 3 ). Thirteen of the 17 were children aged ≤5 years, and 15 of the patients were enrolled in year 3 (see below for resistance rates). In 10 of 17 patients, viral loads in the sample in which resistant virus was first detected were too low to culture. By day 10, influenza virus could not be detected by RT-qPCR in 10 of 15 patients tested (2 patients were not tested on day 10). All 5 patients in whom H275Y was detected at day 10 were children aged 1-6 years, and all had insignificant symptoms from day 6 onward (combined symptom scores of ≤2). A 1-year-old patient with H275Y infection on day 6 but virus-negative on day 10 had a prolonged illness course, with moderate or minor symptoms up to day 14 and persistent anorexia. In phenotypic assays of post-day 1 cultured samples, 8 samples from 7 oseltamivir-treated patients were extreme outliers to oseltamivir (IC 50 , 7.6-130 nM); all were found to carry H275Y, detected either by mutation-specific RT-PCR (original swab) or NA sequencing (cultured sample) or both (Supplementary Tables 3 and 4 ). In samples from 2 patients, H275Y was detected by only 1 testing method, including an adult patient whose day 6 sample was H275Y-positive by NA sequencing but not by mutation-specific RT-PCR; he was virus-negative on day 10 and his symptoms resolved by day 8. Two of the 5 post-day 1 H1N1pdm2009 phenotypic outlier samples were associated with a known resistance mutation (H275Y), and agreement between resistance testing methods for H1N1pdm2009 samples (concordance) was generally good (Supplementary Data).
Infections With Other Influenza Types/Subtypes
In 2 patients infected with H3N2 viruses, the R292K resistance mutation was detected by mutation-specific RT-PCR in a single uncultured swab sample collected after day 1 (Supplementary Table 3 ). Both patients (aged 2 and 20 years) were oseltamivir-treated outpatients enrolled in year 3 (see below for resistance rates). Viral loads in all postbaseline samples from these patients were too low to isolate in cell culture. By day 10, influenza virus could not be detected by RT-qPCR in either patient (or on day 6 in the adult). All symptoms resolved by day 6. In phenotypic assays of post-day 1 cultured samples, no samples from H3N2-infected patients were extreme outliers or outliers to oseltamivir. Sequencing analysis did not identify any known resistance mutations.
No mutation-specific RT-PCR testing was performed for influenza B viruses. In phenotypic assays of post-day 1-cultured samples, no samples from influenza B-infected patients were extreme outliers to oseltamivir; 2 postbaseline samples were outliers to zanamivir (IC 50 , 7.8 and 8.8 nM; Supplementary Table 4) . No known resistance mutations or nonpolymorphic changes that could account for these IC 50 phenotypes were identified by sequencing. Results from the 3 resistance testing methods were concordant for H3N2 and influenza B viruses.
Resistance Rates
The prevalence of emergent resistance in all treated IRIS patients over 3 years was 2.2% (all in influenza A infections; Table 4 ). The highest rate calculated, 12.9%, was for H1N1pdm2009 in young children (aged 1-5 years). Rates were also calculated for all patients in the study: 2.0% in all H1N1pdm2009 patients and 1.1% in all influenza-infected patients, for comparison with rates from studies where no treatment information is available.
Regression and Other Analyses
In a multivariable logistic regression analysis of 886 H1N1pdm2009 cases, treatment with oseltamivir (P < .0001) and time of enrollment (most resistant cases were enrolled in year 3 [2010] [2011] ; P = .002) were significantly associated with emergence of a resistant genotype. Resistance was also more likely to emerge in children, as indicated by a significant association with age (P = .001). History of cardiovascular disease (P = .014) was also significant. Genotypic resistance in H1N1pdm2009 patients was significantly associated with the proportion who cleared virus before day 6 as detected by RTqPCR: in patients treated with oseltamivir monotherapy within 48 hours of illness onset, the proportions were 1 of 17 (5.9%) and 165 of 410 (40.2%) patients with and without the H275Y virus, respectively (P = .004). Results in all patients (irrespective of treatment) were similar, with proportions of 1 of 17 (5.9%) and 320 of 815 (39.3%), respectively (P = .004). For the proportions who achieved symptom resolution before day 6 (score of <1 for each symptom), there was no significant difference between H275Y patients (10/17 [58.8%]) and patients with wild-type strain (239/402 [59.4%]).
DISCUSSION
IRIS is the largest global survey of NAI resistance yet performed in a clinical care setting. In contrast to surveillance by bodies such as the World Health Organization [11] and the Centers for Disease Control and Prevention, demographic and clinical details of the study population were collected, as well as follow-up data for treated and untreated participants. We found a low rate of treatment-emergent resistance in adults and a higher rate in young children, consistent with prior reports from much smaller studies [3-5, 12, 13] . In logistic regression analysis, we found that age was significantly correlated with emergence of genotypic resistance (H275Y) in patients with H1N1pdm2009 infections. Children, especially the very young, are immunologically naive to influenza viruses [14] , and viral replication is therefore greater, allowing selective pressure to induce resistance. A recently completed study reported higher quantities of both virus and viral RNA at presentation in children aged <2 years than adults ( performed by the same laboratory) [15] . That study, like ours, utilized highly sensitive RT-PCR methods to quantify virus and detect specific mutations. With advancing age, exposure of the immune system to influenza virus enables faster clearance.
The rate of emergent H275Y-associated resistance in patients with H1N1pdm2009 infections was significantly higher in year 3 of the study (2010-2011) than the first 2 years. As this viral strain evolves and becomes more diverse, emergent resistance mutations could increase. Because the same RT-PCR assay was used for years 2 and 3, the higher rate in year 3 is unlikely to be solely due to the use of the new assay, and other groups have published relatively high rates of resistance, especially in children [4, 5] . Phylogenetic differences between infecting viruses in years 1-3 of IRIS are currently being analyzed.
Although mutations associated with decreased susceptibility to NAIs, specifically to oseltamivir, were detected, associated viral loads were mostly too low for culturing. Mutant strains often failed to persist, being undetectable by RT-qPCR in twothirds of patients tested by day 10. Patients infected with these strains had neither a protracted disease course nor complications from influenza, perhaps with the exception of 1 child. While there was no apparent difference in resolution of symptoms between patients infected with H275Y mutant strains and those infected with sensitive strains, statistical analysis based on a single cutoff point suggested that viral clearance was slower in the former, probably because prolonged viral shedding increased the risk of H275Y development. However, the effect on viral clearance and disease course of known or novel resistance mutations in more virulent virus strains are unpredictable. Although we have presented statistical analysis of differences between treated and untreated patients with respect to viral clearance and symptom resolution, assessing the effect of treatment on these outcomes was not an objective of the study, and the results are subject to inherent biases of observational studies, for example, patient inclusion, as well as decisions to treat. Important questions arise from recent experience with the NAIs. Reported transmission of resistant strains of H1N1pdm2009 in Australia [16] raised concerns that this phenomenon might become more common. Our study found resistant viruses were rare, suggesting that the Australian experience could be an isolated episode, although our data also suggest that treatment-emergent resistance to H1N1pdm2009 viruses has become more common in the community, a trend which needs continued monitoring. A second question is whether tissue oseltamivir levels achieved after standard dosing regimens are sufficient to inhibit influenza B viruses; our results indicate that the susceptibility of this virus type is currently within the range where an inhibitory effect can be expected. Overall, it is encouraging that treatment-induced resistance to the NAIs was not seen frequently in physicians' practices; where it was seen (in H1N1pdm2009 and H3N2 viruses), there was little effect on disease outcome. Two more years of enrollment in IRIS will provide further information on the clinical implications of resistance in influenza viruses, in immunosuppressed as well as immunocompetent patients.
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